TOKYO: A health scare grips Japan as two deaths and over 100 hospitalizations are linked to dietary supplements aimed at lowering cholesterol, prompting investigations by authorities.
Japanese drugmaker Kobayashi Pharmaceutical recalls three supplement brands containing red yeast rice after reports of kidney complaints from consumers.
Red yeast rice, touted as an alternative to statins for cholesterol management, is under scrutiny for potential organ damage based on its chemical composition.
Government spokesman Yoshimasa Hayashi confirms two deaths and 106 hospitalizations possibly linked to the recalled supplements, urging thorough investigations.
Kobayashi Pharmaceutical, the supplement’s manufacturer, cautions against definitive conclusions on the causal link between its products and health issues, but extends apologies and vows to investigate further.
The company’s share price plummets, and dozens of other firms issuing recalls of products containing beni koji supplied by Kobayashi Pharmaceutical.
Health Minister Keizo Takemi directs the company to provide prompt information on the situation, while offering condolences to affected individuals.
Analysis of the supplements reveals unexpected ingredients, raising concerns about product safety and quality control.
Red yeast rice, commonly used in traditional medicine, poses risks of side effects such as muscle, kidney, and liver damage if containing high levels of certain compounds.
The incident underscores the importance of stringent regulation and monitoring of dietary supplements to ensure consumer safety.
